Clinical trials: Pioglitazone
Diabetes, Schizophrenia
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
This is a study with an approved drug for treating type 2 diabetes, for its effects on treating glucose and lipid abnormalities in patients being treated with first or second-generation antipsychotics, and comparison of effects…
- Conditions
- Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
- Trial name
- NCT00231894
- Testing
- Pioglitazone, Life style diet group
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Asthma, Obesity
Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)
Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.
- Trial name
- GLITZ (NCT00787644)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Vermont
HIV-1 and Hepatitis C Co-Infection
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes.
- Trial name
- NCT00665353
- Testing
- pioglitazone, peginterferon, ribavirin
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Type 2 Diabetes, Healthy
Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
Pioglitazone, a drug used in treatment of type 2 diabetes has been shown to improve insulin sensitivity in skeletal muscle, liver, and fat cells.
- Conditions
- Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
- Trial name
- PIO-EX (NCT00845182)
- Testing
- Pioglitazone, Exenatide, Pioglitazone and Exenatide
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Atherosclerosis, Coronary Artery Disease
The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)
This study is a prospective randomized clinical trial and to compare the antiinflammatory effect of atorvastatin single therapy and atorvastatin and pioglitazone combination therapy in carotid arteries of stable and unstable…
- Trial name
- PIONEER (NCT01341730)
- Testing
- Atorvastatin 20mg, Atorvastatin 20 mg + Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- The Catholic University of Korea
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- BOOST™ (NCT01009580)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 53 sites in Australia, Denmark and 8 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Platelet Function
Effects of Pioglitazone on Platelet Function
The purpose of this study is to determine how pioglitazone and aspirin affect platelets in the blood of diabetic and non-diabetic subjects. Platelets are small cells in the blood that help with blood clotting.
- Conditions
- Diabetes, Platelet Function, Healthy
- Trial name
- UHEM08014 (NCT00861341)
- Testing
- Aspirin, Pioglitazone
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.
- Trial name
- NCT01175824
- Testing
- Insulin Lispro Low Mixture (LM), Insulin Glargine, Prandial Insulin Lispro
- Where
- 18 sites in Argentina, Brazil and 6 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Healthy
Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components
The objective of the current study is to establish the bioequivalence of linagliptin/ pioglitazone fixed dose combination tablet compared to single tablets of linagliptin and pioglitazone administered together.
- Trial name
- NCT01276327
- Testing
- Linagliptin + Pioglitazone, Linagliptin/Pioglitazone
- Where
- Germany
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
A 30-week extension to a 24-week study assessing the hemoglobin A1c (HbA1c)- and fasting plasma glucose (FPG)-lowering efficacy of the combination of sitagliptin and pioglitazone in patients with type 2 diabetes mellitus (T2DM)…
- Trial name
- NCT01028391
- Testing
- Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d., Metformin
- Volunteers
- 317 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Overweight With Indications for Weight Loss
Optimizing Body Composition for Function in Older Adults
The purpose of this pilot study is to compare two strategies intended to improve the health of overweight older adults by improving body composition.
- Trial name
- NCT00315146
- Testing
- Pioglitazone, Resistance exercise training to maximize muscle power, Hypocaloric diet
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Type 2 Diabetes Mellitus
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
Type-2 diabetes mellitus is a public health concern. Patients with type 2 diabetes mellitus are at high risk of developing cardiovascular complications.
- Trial name
- NCT01040819
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
Pioglitazone in Thyroid Cancers
Through this trial the investigators hope to learn if a drug, Actos (pioglitazone), is useful in treating a certain kind of metastatic thyroid cancer. Actos is approved by the FDA to treat diabetes.
- Trial name
- NCT01655719
- Testing
- Pioglitazone
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Polycystic Ovary Syndrome (PCOS) and Sleep Apnea
Polycystic ovary syndrome (PCOS) affects 5-10% of women in the United States. Its onset is usually at the time of puberty with manifestations of menstrual irregularity, hirsutism, and obesity.
- Trial name
- NCT00203996
- Testing
- continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Chicago
HIV Infections
HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
This study is being done to better understand why people with HIV who have taken drugs for HIV begin to show abnormal changes in fat loss or fat gain in their bodies. This condition is called lipodystrophy.
- Trial name
- HAL (NCT01023620)
- Testing
- Pioglitazone, Observation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus, Type 2
Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (Linagliptin) (5 mg / once daily) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg…
- Trial name
- NCT00641043
- Testing
- Linagliptin + pioglitazone (30 mg)
- Where
- 43 sites in Austria, Greece and 5 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
- Trial name
- NCT00432276
- Testing
- Alogliptin, Pioglitazone, Metformin
- Where
- 86 sites in United States
- Volunteers
- 803 people
- Sponsor
- Takeda
Type 2 Diabetes
Add-on to Thiazolidinedione (TZD) Failures
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone.
- Trial name
- NCT00683878
- Testing
- Dapagliflozin, Thiazolidinedione (Pioglitazone)
- Where
- 89 sites in United States, Argentina and 7 more
- Volunteers
- 972 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
- Trial name
- NCT00760578
- Testing
- Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
- Where
- 8 sites in United States
- Volunteers
- 86 people
- Sponsor
- Metabolic Solutions Development Company
Osteoporosis, Type 2 Diabetes Mellitus
Effect of Diabetic Medications on Bone Metabolism
Subjects with diabetes and pre-diabetes are said to have increased bone loss when compared to the general population. Pioglitazone a thiazolidinedione, is a Food and Drug Administration (FDA) approved oral anti-diabetic agent for…
- Trial name
- NCT00467285
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development